In-vitro activity of a new penem FCE 22101

J Antimicrob Chemother. 1989 Mar:23 Suppl C:53-7. doi: 10.1093/jac/23.suppl_c.53.

Abstract

The in-vitro activity of a new penem FCE 22101 was evaluated in comparison with other antimicrobial agents against 966 aerobic and anaerobic Gram-negative and Gram-positive bacteria. FCE 22101 inhibited 90% of Enterobacteriaceae, Haemophilus influenzae, H. parainfluenzae, H. ducreyi, Neisseria gonorrhoeae, Branhamella catarrhalis, Staphylococcus aureus, Staph. epidermidis and group B streptococcus at concentrations of 0.12-4.0 mg/l. Pseudomonas aeruginosa was resistant with MIC90 of greater than 32 mg/l. Streptococcus faecalis displayed MIC90 of 16 mg/l. Bacteroides fragilis, Clostridium spp., Peptococcus spp. and Peptostreptococcus spp. were inhibited at concentrations of 0.25-2.0 mg/l. beta-Lactamase-producing or methicillin resistant bacteria did not have significantly elevated MICs. FCE 22101 was generally less active than imipenem but more active than other beta-lactam antibiotics examined.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Bacteria / enzymology
  • Bacterial Infections / microbiology*
  • Carbapenems*
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / enzymology
  • Gram-Positive Bacteria / drug effects
  • Gram-Positive Bacteria / enzymology
  • Microbial Sensitivity Tests
  • beta-Lactamases / metabolism
  • beta-Lactams

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactams
  • ritipenem
  • beta-Lactamases